Palmitoyl Hexapeptide-12

This six-amino-acid peptide is joined to palmitic acid to support skin delivery. Its core derives from an elastin fragment, placing it among matrikine signal peptides intended to influence skin-support biology. Sederma/Croda markets the ingredient as Biopeptide EL.

Some labels also use “palmitoyl oligopeptide,” an ambiguous naming convention. Chemical identity and the actual finished formulation matter more than a broad trade or ingredient-family name.

Cell models report greater fibroblast production of elastin, glycosaminoglycans and collagen and reduced interleukin-6 signaling. Ex-vivo human-skin work describes self-assembly, outer-layer penetration and reinforcement of a stripped or weakened barrier.

Elastin fragments have mixed biology and can promote inflammation at some concentrations, so a favorable effect cannot be assumed from mechanism alone. Cosmetic goals concern the appearance of firmer, smoother, more resilient skin.

Anti-aging and barrier-support serums or moisturizers use the ingredient for the look of firmness, elasticity, texture and fine lines. It is a cosmetic ingredient rather than an approved medicine.

FDA does not preapprove cosmetic ingredients. Claims about appearance/feel differ from claims to rebuild body elastin, which would enter drug-claim territory.

No independent human appearance-efficacy trial is described; claims principally rest on manufacturer and laboratory findings. It is considered low-irritation at cosmetic use levels, but clinical safety data remain limited and a sensitive-skin patch test is reasonable.